Cummings, J., Ranson, M., LaCasse, E., Ganganagari, J. R., St-Jean, M., Jayson, G., . . . Dive, C. (2006). Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Nature Publishing Group.

Cummings, J., M. Ranson, E. LaCasse, J R. Ganganagari, M. St-Jean, G. Jayson, J. Durkin, and C. Dive. Method Validation and Preliminary Qualification of Pharmacodynamic Biomarkers Employed to Evaluate the Clinical Efficacy of an Antisense Compound (AEG35156) Targeted to the X-linked Inhibitor of Apoptosis Protein XIAP. Nature Publishing Group, 2006.

Cummings, J., et al. Method Validation and Preliminary Qualification of Pharmacodynamic Biomarkers Employed to Evaluate the Clinical Efficacy of an Antisense Compound (AEG35156) Targeted to the X-linked Inhibitor of Apoptosis Protein XIAP. Nature Publishing Group, 2006.